Last reviewed · How we verify

conventional analgesia

Ain Shams University · FDA-approved active Small molecule ✓ Verified Jun 2026 Quality 5/100

conventional analgesia is a Small molecule drug developed by Ain Shams University. It is currently FDA-approved.

Conventional analgesia involves interventions such as Transcutaneous Electrical Nerve Stimulation, hotpack, and parasternal block to manage pain in conditions like postoperative pain and knee osteoarthritis. These interventions are typically used in conjunction with conventional physical therapy, and their efficacy has been studied in clinical trials such as NCT06418360, which evaluated the effectiveness of TECAR therapy in patients with knee osteoarthritis.

At a glance

Generic nameconventional analgesia
SponsorAin Shams University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about conventional analgesia

What is conventional analgesia?

conventional analgesia is a Small molecule drug developed by Ain Shams University.

Who makes conventional analgesia?

conventional analgesia is developed and marketed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).

What development phase is conventional analgesia in?

conventional analgesia is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing